Pfizer Looks Like A Great Play At Current Valuations

Summary

• Pfizer is an attractive value play, trading at a significant discount despite strong profitability and growth fundamentals versus peers.
• The company leads its peer group in EBITDA and revenue growth, while maintaining solid margins and forward growth expectations.
• Risks include increased competition in the ATTR-CM market and ongoing technical downtrends, but cost-cutting measures may enhance efficiency.
• I rate PFE a clear buy at current levels, but recommend buying in tranches to manage potential further price declines.